Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALA NASDAQ:CTMX NYSE:LCI NASDAQ:MGTA NASDAQ:MRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00$0.00▼$0.05N/A-2.8213,198 shs241 shsCTMXCytomX Therapeutics$2.49+3.8%$2.17$0.40▼$3.10$193.49M2.052.19 million shs2.16 million shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsMGTAMagenta Therapeutics$0.70-7.7%$0.53$0.32▼$2.07$42.44M2.12848,835 shs376,000 shsMRSNMersana Therapeutics$0.34+3.1%$0.35$0.26▼$2.83$40.75M0.792.72 million shs3.11 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%-95.00%-90.00%-99.50%CTMXCytomX Therapeutics+3.75%+0.40%-5.32%+403.44%+84.44%LCILannett0.00%0.00%0.00%0.00%0.00%MGTAMagenta Therapeutics0.00%0.00%0.00%0.00%0.00%MRSNMersana Therapeutics+3.12%+20.56%-13.72%+29.00%-82.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACTMXCytomX Therapeutics3.9219 of 5 stars3.51.00.04.70.61.71.3LCILannettN/AN/AN/AN/AN/AN/AN/AN/AMGTAMagenta TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMRSNMersana Therapeutics3.6628 of 5 stars3.51.00.04.11.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/ACTMXCytomX Therapeutics 3.00Buy$5.33114.19% UpsideLCILannett 0.00N/AN/AN/AMGTAMagenta Therapeutics 0.00N/AN/AN/AMRSNMersana Therapeutics 3.00Buy$5.201,442.11% UpsideCurrent Analyst Ratings BreakdownLatest CALA, MRSN, LCI, MGTA, and CTMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025MRSNMersana TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/16/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.005/16/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/15/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.005/15/2025CTMXCytomX TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00 ➝ $5.005/15/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$3.005/12/2025CTMXCytomX TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.00 ➝ $6.005/6/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $3.004/14/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.50(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/ACTMXCytomX Therapeutics$138.10M1.45$0.38 per share6.63($0.01) per share-249.00LCILannett$340.58M0.00N/AN/A($23.34) per share0.00MGTAMagenta TherapeuticsN/AN/AN/AN/A$1.23 per shareN/AMRSNMersana Therapeutics$40.50M1.04N/AN/A($0.08) per share-4.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACTMXCytomX Therapeutics$31.87M$0.485.19N/AN/A28.22%-553.71%32.21%8/14/2025 (Estimated)LCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/AMGTAMagenta Therapeutics-$76.46MN/A0.00∞N/AN/A-70.88%-57.27%N/AMRSNMersana Therapeutics-$69.19M-$0.59N/AN/AN/A-217.63%-990.16%-48.87%8/12/2025 (Estimated)Latest CALA, MRSN, LCI, MGTA, and CTMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MRSNMersana Therapeutics-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million5/12/2025Q1 2025CTMXCytomX Therapeutics$0.18$0.27+$0.09$0.27$35.42 million$50.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AMGTAMagenta TherapeuticsN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/ACTMXCytomX TherapeuticsN/A1.731.73LCILannettN/A2.231.39MGTAMagenta TherapeuticsN/A19.4919.49MRSNMersana TherapeuticsN/A1.831.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ACTMXCytomX Therapeutics67.77%LCILannett40.28%MGTAMagenta Therapeutics47.53%MRSNMersana Therapeutics93.92%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%CTMXCytomX Therapeutics6.60%LCILannett13.12%MGTAMagenta Therapeutics15.18%MRSNMersana Therapeutics13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableCTMXCytomX Therapeutics17080.62 million75.30 millionOptionableLCILannett81010.77 million9.35 millionOptionableMGTAMagenta Therapeutics6760.67 million51.46 millionNot OptionableMRSNMersana Therapeutics150124.63 million108.43 millionOptionableCALA, MRSN, LCI, MGTA, and CTMX HeadlinesRecent News About These CompaniesMersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Buy" by BrokeragesJuly 5, 2025 | americanbankingnews.comMersana Therapeutics Settles Debt with Oxford FinanceJuly 3, 2025 | tipranks.comMersana Therapeutics Inc (MRSN) - Investing.comJuly 2, 2025 | investing.comMersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual MeetingJune 2, 2025 | globenewswire.comMersana Therapeutics to Present at Upcoming Investor ConferencesMay 20, 2025 | globenewswire.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comQ1 2025 Mersana Therapeutics Inc Earnings CallMay 16, 2025 | uk.finance.yahoo.comMersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ...May 16, 2025 | finance.yahoo.comMersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancerMay 15, 2025 | msn.comCORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsMay 15, 2025 | finance.yahoo.comCORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsMay 15, 2025 | globenewswire.comMersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comMersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsMay 15, 2025 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsMay 15, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and IQVIA Holdings (IQV)May 9, 2025 | theglobeandmail.comMersana Therapeutics announces strategic cutbacks amid economic pressuresMay 7, 2025 | investing.comMersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADCMay 6, 2025 | fiercebiotech.comFMersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast CancerMay 6, 2025 | globenewswire.comWhy Mersana Therapeutics, Inc.’s (MRSN) Stock Is Down 8.13%May 2, 2025 | aaii.comAMersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual MeetingApril 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeCALA, MRSN, LCI, MGTA, and CTMX Company DescriptionsCalithera Biosciences NASDAQ:CALA$0.0001 0.00 (0.00%) As of 07/8/2025 03:13 PM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.CytomX Therapeutics NASDAQ:CTMX$2.49 +0.09 (+3.75%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$2.52 +0.03 (+1.41%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Lannett NYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Magenta Therapeutics NASDAQ:MGTAMagenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Mersana Therapeutics NASDAQ:MRSN$0.34 +0.01 (+3.12%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$0.35 +0.01 (+2.91%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will Oracle's Cloud and AI Deals Propel It to New Highs? Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
